Compare HCI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | ANIP |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | 594 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 1999 |
| Metric | HCI | ANIP |
|---|---|---|
| Price | $163.17 | $82.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $230.00 | $110.00 |
| AVG Volume (30 Days) | 133.6K | ★ 274.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $11.44 | $21.01 |
| Revenue Next Year | $7.67 | $17.59 |
| P/E Ratio | ★ $9.97 | $63.81 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $136.37 | $62.61 |
| 52 Week High | $210.50 | $99.50 |
| Indicator | HCI | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 58.41 |
| Support Level | $148.86 | $76.73 |
| Resistance Level | $169.48 | $83.61 |
| Average True Range (ATR) | 4.75 | 2.27 |
| MACD | 1.00 | 0.36 |
| Stochastic Oscillator | 87.46 | 89.81 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.